Performance & Vitality · Reviewed by Ian K. Tseng, MD

What Is Sermorelin? How a GHRH Analog Differs From HGH

Sermorelin is frequently discussed as a substitute for human growth hormone. Mechanistically, that framing gets it backwards. Sermorelin does not replace growth hormone — it asks your pituitary to release more of its own. That difference has real consequences for how the therapy behaves in the body and what a physician monitors.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Soothe IV Med Spa branded amber pharmacy vial on warm marble, representing the performance & vitality category of physician-supervised peptide therapy

The short answer

Sermorelin is a synthetic analog of growth-hormone-releasing hormone, consisting of the first 29 amino acids of the natural GHRH molecule — the shortest fragment that retains full biological activity. It binds GHRH receptors on the pituitary and stimulates the release of your own endogenous growth hormone in the body's natural pulsatile pattern, with the feedback loop that normally regulates that release left intact.

The signal versus the hormone

Growth hormone is released by the anterior pituitary under the direction of two opposing signals from the hypothalamus: growth-hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which suppresses it. The interplay of these two produces the characteristic pattern of GH secretion — pulses, concentrated heavily during deep sleep, rather than a steady level.

Injecting growth hormone directly bypasses this system entirely. It raises circulating GH regardless of what the hypothalamus is signaling, and sustained exogenous GH suppresses the body's own production through negative feedback.

Sermorelin operates one step upstream. It acts on the pituitary as GHRH does, prompting release rather than supplying the hormone. Because the downstream feedback loop remains functional — including somatostatin's braking action — the resulting GH release retains its pulsatile character and remains subject to the body's own regulatory ceiling.

Why the pulsatile pattern is discussed so much

Growth hormone signaling appears to be sensitive not only to how much GH is present but to the pattern in which it arrives. Physiologic GH release is pulsatile, and the literature discussing GHRH analogs generally frames preservation of that pattern as the mechanistic rationale for the approach.

It is worth being precise about what this does and does not establish. That a therapy preserves a physiologic pattern is a mechanistic argument, not by itself proof of superior clinical outcomes. Research in this area continues, and individual response varies.

Regulatory history worth knowing

Sermorelin held FDA approval and was marketed under a brand name for use in assessing growth hormone deficiency. It was withdrawn from the market in 2008. That withdrawal was a commercial decision by the manufacturer, not a safety action by the FDA — a distinction that gets lost in online discussion, where the withdrawal is sometimes presented as evidence of a safety problem.

Sermorelin available today is a compounded preparation, produced by a compounding pharmacy against an individual prescription. It has not been through FDA pre-market review in that form.

IGF-1 and the monitoring that matters

Growth hormone itself is difficult to measure usefully in a single blood draw, precisely because it is released in pulses — a level drawn between pulses tells you little. Clinical monitoring of the GH axis therefore relies substantially on insulin-like growth factor 1 (IGF-1), which is produced largely in the liver in response to GH and circulates at a comparatively stable level.

A baseline IGF-1 is required before starting any growth-hormone-axis therapy, and it is retested during treatment. Alongside it, a physician reviews fasting glucose and insulin — GH affects insulin sensitivity — plus thyroid function and a general metabolic panel. Our bloodwork explainer covers what each of these is doing.

The most important contraindication is active malignancy. Because the GH/IGF-1 axis is growth-promoting, GHRH analogs are not appropriate in the setting of active cancer, and screening history is part of the Good Faith Exam.

Frequently asked questions

Is sermorelin the same as HGH?

No, and the mechanism is meaningfully different. HGH is growth hormone itself, injected directly, which raises circulating levels regardless of the body's own signaling and suppresses endogenous production through negative feedback. Sermorelin is a GHRH analog that acts one step upstream on the pituitary, prompting release of your own growth hormone while leaving the natural feedback loop and pulsatile release pattern intact.

Why was sermorelin withdrawn from the market in 2008?

The withdrawal was a commercial decision by the manufacturer, not an FDA safety action. This distinction is frequently misrepresented online. Sermorelin available today is a compounded preparation prescribed individually, which has not been through FDA pre-market review in that form.

What bloodwork is required before sermorelin?

A baseline IGF-1 is required, because growth hormone itself is released in pulses and is difficult to interpret from a single draw, while IGF-1 circulates at a comparatively stable level and reflects GH activity. A physician also reviews fasting glucose and insulin, thyroid function, and a general metabolic panel. IGF-1 is retested during therapy.

Who should not take a GHRH analog?

Active malignancy is the primary contraindication, because the growth hormone and IGF-1 axis is growth-promoting. Other considerations include uncontrolled diabetes, given the effect of growth hormone on insulin sensitivity, and untreated pituitary or thyroid disorders. Screening for these is part of the Good Faith Exam.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. pubmed.ncbi.nlm.nih.gov
Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020. pmc.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. Human Drug Compounding. www.fda.gov

Ready to talk to a physician?

Start your $50 Application — the comprehensive intake, physician Good Faith Examination, and medical clearance. A physician reviews your goals and labs and tells you honestly whether therapy is appropriate. Your fee credits in full toward your first month of membership. Available nationwide.

Book & Pay for Your $50 Application

Serving Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.